Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE with celecoxib and/or lanreotide for hepatocellular carcinoma
ChiCTR-TRC-11000173Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2007
- Modality
- Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lanreotide and celecoxib in hepatocellular carcinoma (HCC) (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Survival time and survival rate. Started Dec 2007; status: completed.
02
Drugs
lanreotidecelecoxib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-TRC-11000173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11000173.